Liquidia Reports Strong YUTREPIA Sales, Reduced Losses Amid Critical Patent Litigation

summarizeSummary

Liquidia Corp reported strong 2025 revenue growth from its YUTREPIA launch, significantly reducing net losses, but faces critical patent and trade secret litigations that threaten its market access and a $70.6M antitrust judgment under appeal.

check_boxKey Events

• Strong Revenue Growth & Reduced Losses

  Total revenue for 2025 surged to $158.3 million, primarily from $148.3 million in net product sales of YUTREPIA, which launched in June 2025. This led to a reduced net loss of $68.9 million in 2025, down from $128.3 million in 2024, with the company achieving profitability and positive operating cash flow in Q3 and Q4 2025.

• Critical Patent Litigation Overhang

  Liquidia is embroiled in multiple patent and trade secret litigations with United Therapeutics, including the '327 Patent Litigation (decision pending after June 2025 trial) and '782 Patent Litigation, both seeking injunctions to remove YUTREPIA from the market or limit its PH-ILD indication. A separate trade secret lawsuit also seeks injunctive relief and monetary damages.

• $70.6M Litigation Judgment Under Appeal

  A court entered a $70.6 million judgment in November 2024 in the RareGen antitrust litigation, with proceeds to be split between Sandoz and Liquidia PAH, and further allocated to litigation funders. All parties have appealed the decision, with oral arguments held in November 2025 and a decision pending.

• Generic Treprostinil Supply Constraint

  Sales of the generic Treprostinil Injection product are constrained by the discontinuation of the CADD-MS 3 infusion pump by ICU Medical, with existing supply only sufficient until at least the end of 2026. Efforts to develop a replacement pump are ongoing, but no FDA 510(k) clearance application has been submitted.

auto_awesomeAnalysis

Liquidia Corp reported a significant financial turnaround in 2025, driven by the successful commercial launch of YUTREPIA, which generated $148.3 million in net product sales and substantially reduced the company's net loss. The company achieved profitability and positive operating cash flow in the latter half of 2025, indicating strong commercial momentum for its flagship product. However, this positive performance is overshadowed by multiple ongoing, high-stakes patent and trade secret litigations with United Therapeutics. These lawsuits seek injunctive relief that could potentially remove YUTREPIA from the market or restrict its approved indications, posing a critical threat to the company's primary revenue stream. Additionally, a $70.6 million judgment was awarded in the RareGen antitrust litigation, though this is currently under appeal and its net financial impact to Liquidia is subject to profit-sharing and litigation finance agreements. The company also faces operational challenges with its generic Treprostinil Injection product due to the discontinuation of a key infusion pump, which could constrain future sales until an alternative is secured. Despite these risks, Liquidia is advancing its L606 product candidate into a pivotal Phase 3 study, indicating continued pipeline development. Investors should closely monitor the outcomes of the various litigations, as they represent a significant source of uncertainty and potential downside risk to the company's commercialization efforts and financial outlook.